Self nanoemulsifying drug delivery system of olanzapine for enhanced oral bioavailability: In vitro, In vivo characterisation and In vitro -In vivo correlation

Journal of Bioequivalence and Bioavailability

Volumn 5, Issue 5, 2013, Pages

  Suresh Kumar, Raman ^a   Sri Syamala, Urmila ^a   Revathi, Punukollu ^a   Sumanth, Devaki ^a   Raghuveer, Pathuri ^a   Gowthamarajan, Kuppuswamy ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Biorelavent dissolution media; Ivivc; Olanzapine; SNEDDS

Indexed keywords

ALCOHOL; ARACHIS OIL; CASTOR OIL; LINSEED OIL; OLANZAPINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONDUCTANCE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; DRUG POTENCY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PREDICTION; RABBIT; REFRACTION INDEX; RELIABILITY; SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM; TABLET FORMULATION; THERMOSTABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; VISCOSITY; ZETA POTENTIAL;

EID: 84885082354     PISSN: None     EISSN: 09750851     Source Type: Journal    
DOI: 10.4172/jbb.1000159     Document Type: Article

References (21)

1. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S (2011) Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications; International Journal of Pharmaceutics 420: 1-10.
2. Pouton CW, Porter CJ (2008) Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev 60: 625-637.
3. Larsen AT, Sassene P, Müllertz A (2011) In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems. Int J Pharm 417: 245-255.
4. Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT (2002) A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 91: 1991-2002.
5. Basalious EB, Shawky N, Badr-Eldin SM (2010) SNEDDS containing bioenhancers for improvement of dissolution and oral absorption of lacidipine. I: development and optimization. Int J Pharm 391: 203-211.
6. Chatsisvili A, Sapounidis I, Pavlidou G, Zoumpouridou E, Karakousis VA, et al. (2010) Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece. Pharm World Sci 32: 187-193.
7. U.S. Department of Health and Human Services (1997) Guidance for industries. Modified release solid oral dosage forms: scale-up and post approval changes: chemistry, manufacturing and controls; in vitro dissolution testing and in vivo bioequivalance documentation.
8. www.fda.gov
9. Jantratid E, De Maio V, Ronda E, Mattavelli V, Vertzoni M, et al. (2009) Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur J Pharm Sci 37: 434-441.
10. Uppoor VR (2001) Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release 72: 127-132.
11. Cheung RY, Kuba R, Rauth AM, Wu XY (2004) A new approach to the in vivo and in vitro investigation of drug release from locoregionally delivered microspheres. J Control Release 100: 121-133.
12. Lu Y, Kim S, Park K (2011) In vitro-in vivo correlation: perspectives on model development. Int J Pharm 418: 142-148.
13. Shafiq-un-Nabi S, Shakeel F, Talegaonkar S, Ali J, Baboota S, et al. (2007) Formulation development and optimization using nanoemulsion technique: a technical note. AAPS PharmSciTech 8.
14. Bouchemal K, Briançon S, Perrier E, Fessi H (2004) Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int J Pharm 280: 241-251.
15. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, et al. (2007) Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 66: 227-243.
16. U.S. Department of Health and Human Services, FDA, Dissolution methods, 2004.
17. Sunesen VH, Pedersen BL, Kristensen HG, Müllertz A (2005) In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur J Pharm Sci 24: 305-313.
18. Fatouros DG, Nielsen FS, Douroumis D, Hadjileontiadis LJ, Mullertz A (2008) In vitro-in vivo correlations of self-emulsifying drug delivery systems combining the dynamic lipolysis model and neuro-fuzzy networks. Eur J Pharm Biopharm 69: 887-898.
19. Shargel L, Wu- Pong S, Andrew BC Yu (2007) Applied Biopharmaceutics & Pharmacokinetics, The Mc Graw Hill Companies.
20. Uppoor VR (2001) Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release 72: 127-132.
21. Bali V, Ali M, Ali J (2010) Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe. Colloids Surf B Biointerfaces 76: 410-420.